Cargando…

Epigallocatechin Gallate Protects against MNNG-Induced Precancerous Lesions of Gastric Carcinoma in Rats via PI3K/Akt/mTOR Pathway

OBJECTIVE: To evaluate the therapeutic effect of epigallocatechin gallate (EGCG) on precancerous lesions of gastric carcinoma (PLGC) and to determine whether EGCG protects against PLGC by regulating PI3K/Akt/mTOR pathway. METHODS: Twenty-four male Wistar rats were randomly divided into 3 groups: nor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Feiye, Xu, Yanli, Pan, Jieli, Li, Meiya, Chen, Fangming, Xie, Guanqun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880711/ https://www.ncbi.nlm.nih.gov/pubmed/33628319 http://dx.doi.org/10.1155/2021/8846813

Ejemplares similares

PTEN/AKT/mTOR signaling mediates anticancer effects of epigallocatechin-3-gallate in ovarian cancer
por: Qin, Jianli, et al.
Publicado: (2020)

Study on the Mechanism of Sancao Tiaowei Decoction in the Treatment of MNNG-Induced Precancerous Lesions of Gastric Carcinoma Through Hedgehog Signaling Pathway
por: Cai, Yan, et al.
Publicado: (2022)

Epigallocatechin gallate (EGCG) attenuates myocardial hypertrophy and fibrosis induced by transverse aortic constriction via inhibiting the Akt/mTOR pathway
por: Cui, Yue, et al.
Publicado: (2021)

Synergistic Carcinogenesis of HPV18 and MNNG in Het-1A Cells through p62-KEAP1-NRF2 and PI3K/AKT/mTOR Pathway
por: Zhang, Ying, et al.
Publicado: (2020)

Epigallocatechin Gallate Relieved PM2.5-Induced Lung Fibrosis by Inhibiting Oxidative Damage and Epithelial-Mesenchymal Transition through AKT/mTOR Pathway
por: Zhongyin, Zhou, et al.
Publicado: (2022)

The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
por: Matsuoka, Tasuku, et al.
Publicado: (2014)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Skin Protective Effect of Epigallocatechin Gallate
por: Kim, Eunji, et al.
Publicado: (2018)

Role of Epigallocatechin Gallate in Glucose, Lipid, and Protein Metabolism and L-Theanine in the Metabolism-Regulatory Effects of Epigallocatechin Gallate
por: Lin, Ling, et al.
Publicado: (2021)

Dipeptidyl Peptidase-4 Is a Target Protein of Epigallocatechin-3-Gallate
por: Hou, Huimin, et al.
Publicado: (2020)

Epigallocatechin-3-Gallate (EGCG) Promotes Autophagy-Dependent Survival via Influencing the Balance of mTOR-AMPK Pathways upon Endoplasmic Reticulum Stress
por: Holczer, Marianna, et al.
Publicado: (2018)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

The Role of Green Tea Catechin Epigallocatechin Gallate (EGCG) and Mammalian Target of Rapamycin (mTOR) Inhibitor PP242 (Torkinib) in the Treatment of Spinal Cord Injury
por: Machova Urdzikova, Lucia, et al.
Publicado: (2023)

Highly‐expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β‐catenin and mTOR/HIF1α/VEGF signaling
por: Zhang, Yingchi, et al.
Publicado: (2019)

Epigallocatechin Gallate Nanodelivery Systems for Cancer Therapy
por: Granja, Andreia, et al.
Publicado: (2016)

Food-Grade Encapsulation Systems for (−)-Epigallocatechin Gallate
por: Shi, Meng, et al.
Publicado: (2018)

Therapeutic Potential of Epigallocatechin Gallate Nanodelivery Systems
por: Granja, Andreia, et al.
Publicado: (2017)

Effect of Epigallocatechin Gallate on Viability of Kudoa septempunctata
por: Shin, Sang Phil, et al.
Publicado: (2020)

Integrating Network Pharmacology and Experimental Verification to Explore the Pharmacological Mechanisms of Aloin Against Gastric Cancer
por: Gao, Jia, et al.
Publicado: (2022)

Effects of epigallocatechin-3-gallate combined with ascorbic acid and glycerol on the stability and uric acid-lowering activity of epigallocatechin-3-gallate
por: Xie, Qianjin, et al.
Publicado: (2021)

Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia
por: Sacco, Antonio, et al.
Publicado: (2010)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
por: Bhatt, Aadra P., et al.
Publicado: (2013)

Targeting the PI3K-AKT-mTOR signaling network in cancer
por: Khan, Khurum H., et al.
Publicado: (2013)

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
por: Fransecky, Lars, et al.
Publicado: (2015)

PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
por: Zhang, Zixuan, et al.
Publicado: (2017)

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
por: Sun, Eun Jin, et al.
Publicado: (2021)

PI3K/AKT/mTOR pathway in tumor progression of oligodendrogliomas
por: Lisi, Lucia
Publicado: (2020)

Roles of PI3K/AKT/mTOR Axis in Arteriovenous Fistula
por: Ratti, Stefano, et al.
Publicado: (2022)

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
por: Zhu, Kunrui, et al.
Publicado: (2022)

Epigallocatechin-3-gallate inhibits inflammation and epithelial-mesenchymal transition through the PI3K/AKT pathway via upregulation of PTEN in asthma
por: Yang, Nan, et al.
Publicado: (2018)

Epigallocatechin-3-gallate and Epigallocatechin-3-O-(3-O-methyl)-gallate Enhance the Bonding Stability of an Etch-and-Rinse Adhesive to Dentin
por: Yu, Hao-Han, et al.
Publicado: (2017)

PTPN14 promotes gastric cancer progression by PI3KA/AKT/mTOR pathway
por: Li, Hui, et al.
Publicado: (2023)

C(18)H(17)NO(6) Inhibits Invasion and Migration of Human MNNG Osteosarcoma Cells via the PI3K/AKT Signaling Pathway
por: Qu, Qianqian, et al.
Publicado: (2019)

Helicobacter pylori infection can modulate the susceptibility of gastric mucosa cells to MNNG
por: Arabski, Michał, et al.
Publicado: (2006)

Effects of (-)-epigallocatechin gallate on RPE cell migration and adhesion
por: Chan, Chi-Ming, et al.
Publicado: (2010)

Broad inhibition of plasmodium falciparum cytoadherence by (+)-epigallocatechin gallate
por: Patil, Pradeep R, et al.
Publicado: (2011)

Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG)
por: Singh, Neha Atulkumar, et al.
Publicado: (2016)

Inhibitory Effects of (−)-Epigallocatechin-3-gallate on Esophageal Cancer
por: Wang, Liu-Xiang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rvhu4pkvu9n5bto88s4lo02g80